2.95%
-0.99%
8.87%
32.04%
74.65%
-65.81%
-81.73%
AI Spotlight on PRAX
Company Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy.
It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Market Data
| Last Price | 76.2 |
| Change Percentage | 2.95% |
| Open | 74.61 |
| Previous Close | 74.02 |
| Market Cap ( Millions) | 1420 |
| Volume | 357391 |
| Year High | 86.93 |
| Year Low | 33.01 |
| M A 50 | 73.99 |
| M A 200 | 59.58 |
Financial Ratios
| FCF Yield | -7.01% |
| Dividend Yield | 0.00% |
| ROE | -54.86% |
| Debt / Equity | 0.43% |
| Net Debt / EBIDTA | 102.01% |
| Price To Book | 3.76 |
| Price Earnings Ratio | -9.53 |
| Price To FCF | -14.27 |
| Price To sales | 884.86 |
| EV / EBITDA | -7.66 |
News
- Jan -13 - Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
- Dec -18 - Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
- Dec -03 - Praxis Precision Medicines to Present at Upcoming December Investor Conferences
- Nov -06 - Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
- Nov -06 - Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
- Nov -06 - Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
- Nov -06 - Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- Nov -01 - Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
- Sep -04 - Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
- Sep -04 - Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
- Sep -03 - Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
- Sep -02 - Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
- Aug -15 - Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
- Aug -13 - Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript
- Aug -13 - Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
- Aug -05 - Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
- Jun -21 - Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
- Jun -04 - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May -17 - Praxis Precision Medicines to Participate in Upcoming Investor Conferences
- May -13 - Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceuticals
Expected Growth : 10.27 %
What the company do ?
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for complex central nervous system disorders.
Why we expect these perspectives ?
Praxis Precision Medicines, Inc.'s pharmaceutical segment growth of 10.27% is driven by increasing demand for personalized therapies, strategic partnerships, and investments in R&D. The company's focus on rare genetic disorders and innovative gene therapies also contributes to its growth. Additionally, expanding product pipelines and regulatory approvals in key markets further support the segment's upward trend.
Praxis Precision Medicines, Inc. Products
| Product Range | What is it ? |
|---|---|
| PRAX-114 | A novel, oral, small molecule designed to modulate the N-methyl-D-aspartate (NMDA) receptor, with potential therapeutic benefits for neurological and psychiatric disorders. |
| PRAX-944 | A novel, oral, small molecule designed to modulate the 5-HT2C receptor, with potential therapeutic benefits for neurological and psychiatric disorders. |
| PRAX-115 | A novel, oral, small molecule designed to modulate the AMPA receptor, with potential therapeutic benefits for neurological and psychiatric disorders. |
Praxis Precision Medicines, Inc.'s Porter Forces
Threat Of Substitutes
Praxis Precision Medicines, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for genetic diseases.
Bargaining Power Of Customers
Praxis Precision Medicines, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for rare genetic disease treatments.
Bargaining Power Of Suppliers
Praxis Precision Medicines, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment, but also due to the specialized nature of some of the inputs required.
Threat Of New Entrants
Praxis Precision Medicines, Inc. has a high threat of new entrants due to the growing interest in genetic medicine and the potential for new companies to enter the market with innovative technologies.
Intensity Of Rivalry
Praxis Precision Medicines, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry among companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.46% |
| Debt Cost | 3.95% |
| Equity Weight | 96.54% |
| Equity Cost | 18.31% |
| WACC | 17.81% |
| Leverage | 3.58% |
Praxis Precision Medicines, Inc. : Quality Control
Praxis Precision Medicines, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OCUL | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company … |
| IMNM | Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| PTGX | Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable … |
| GTHX | G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Protagonist Therapeutics
A-Score
1-Year Total Return ->
🥉
Praxis Precision Medicines
A-Score
1-Year Total Return ->
4
Poseida Therapeutics
A-Score
1-Year Total Return ->
5
G1 Therapeutics
A-Score
1-Year Total Return ->
6
